Jubilant Ingrevia Ltd Q2 FY27 results (latest), Jul–Sep 2026 →Revenue ₹1,394 Cr +24.4% YoYSee revenue, profit and what management said. You are viewing Q1 FY26.
JI

Jubilant Ingrevia Ltd

Q1 FY26Chemicals & Petrochemicals

Jubilant Ingrevia Q1 FY26 earnings call: Revenue & Margins

Q1 FY26 earnings call: what management said on revenue, margins and capex.

Revenue
₹1,038Cr
+1.4% YoY
−1.2% QoQ
Net profit
₹75Cr
+53.1% YoY
+1.4% QoQ
Margin
14%
+3 pp YoY
0 pp QoQ
Price₹718
Market cap₹11.7K Cr
P/E36.9

The short version

Specialty Chemicals and Nutrition segments expected to sustain strong growth; these now contribute ~63% of revenue and 90% of EBITDA. Specialty and Nutrition segments contribute ~63% of revenue and ~90% of EBITDA, expected to sustain strong growth and margin expansion.

From Jubilant Ingrevia Ltd's Q1 FY26 earnings-call transcript · updated 23 Aug 2026.

Revenue & Sales Performance

  • Specialty Chemicals and Nutrition segments expected to sustain strong growth; these now contribute ~63% of revenue and 90% of EBITDA.
  • Anticipated 20%-25% year-on-year growth driven by specialty chemicals and export growth, offsetting feed segment volatility.
  • Pharma CDMO business funnel doubled in last year; strong traction with innovators and tier-1 CDMOs in US, EU, Japan.
  • CDMO agro plant capacity expansion underway; first agro contract deliveries started; big CDMO order supply expected early 2026.
  • Semiconductor segment has 12+ molecules in pipeline; focus on high-value, low-volume products with expected commercial-stage progress.
  • New multi-purpose plants under construction and debottlenecking ongoing to enhance capacity by 15-20%.

2 more points from Jubilant Ingrevia Ltd's call on revenue

Create a free account to keep reading this call

Profitability & Margins

See what Jubilant Ingrevia Ltd said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

  • Rs. 2000 crore invested recently, with 70% allocated to specialty chemicals, mainly for multipurpose and dedicated plants serving CDMO and Fine Chemicals businesses.
  • Major ongoing CAPEX includes a big dedicated plant for an agro CDMO contract at Bharuch, expected to complete by end FY’26.
  • Additional CAPEX projects: new boiler at Bharuch (commissioning expected Q2 FY’26), debottlenecking existing plants at Bharuch and Gajraula to increase capacity by 15-20%, and a new multi-purpose plant (MPP8) at Gajraula with construction starting soon.
  • Niacinamide plant commissioned in March is being converted to a multi-purpose plant for human nutrition.

2 more points from Jubilant Ingrevia Ltd's call on capex

Create a free account to keep reading this call

Top-ranked in Chemicals & Petrochemicals

Ranked on what management guided this quarter

Guidance-ranked
2Shiv Texchem
Rev 1Mar 2
3
Rev 1Mar 3
4
Rev 1Mar 3
5
Rev 1Mar 3
Sign up free to see 3 moreTakes 30 seconds · no cardSign up

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

See what Jubilant Ingrevia Ltd said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

  • Jubilant Ingrevia has a robust CDMO order book with over 70 active molecules in the pipeline, representing a multi-thousand crore addressable market.
  • The pharma segment funnel has doubled in the last year, engaging with over 30 key global accounts across EU, US, and Japan.
  • In agro CDMO, the company has announced two contracts last year and expects 5-6 more contracts in advanced stages, with deliveries already started on the first agro CDMO order.
  • A significant $300 million agro CDMO contract is in execution, with plant commissioning and supplies expected early 2026.

2 more points from Jubilant Ingrevia Ltd's call on order book

Create a free account to keep reading this call

Jubilant Ingrevia Ltd — Quarterly revenue & net profit

Revenue Net profit
Jun 2025Q1 FY26
Sep 2025Q2 FY26
Dec 2025Q3 FY26
Mar 2026Q4 FY26
Jun 2026Q1 FY27
Sep 2026Q2 FY27

Jubilant Ingrevia Ltd Q1 FY26 results — key figures

Jubilant Ingrevia Ltd Q1 FY26 reported results vs Q1 FY25, ₹ crore
₹ CrQ1 FY26Q1 FY25YoYQ4 FY25QoQ
Revenue1,0381,024+1.4%1,051-1.2%
Operating profit (EBITDA)142110+29.1%147-3.4%
Operating margin14%11%+3 pp14%0 pp
Profit before tax10066+51.5%102-2%
Net profit (PAT)7549+53.1%74+1.4%
EPS (₹)4.713.06+53.9%4.65+1.3%

Source: reported quarterly figures (Screener), ₹ crore.

Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹1.4K Cr, net profit ₹111 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

Others in Chemicals & Petrochemicals this season

  • Balaji Amines (Q1 FY26)

    Q1FY26 consolidated revenue from operations: ₹367 crore, up 2% quarter-on-quarter from ₹361 crore in Q4FY25, but down 7% year-on-year from ₹393 crore in Q1FY25…

  • Linde India (Q1 FY26)

    Net Revenue for FY ended Mar’25 was INR 24,854 million, down 10.2% (–2,833 million) YoY from INR 27,687 million. Key concall takeaways from Linde India Ltd's…

  • Vidhi Specialty (Q1 FY26)

    87.9 Crores . Key concall takeaways from Vidhi Specialty Food Ingredients Ltd's Q1 FY26 earnings call — and how it ranks against sector peers.

  • Chemcon Speciality Chemicals (Q1 FY26)

    Q1 FY26 revenue from operations: ₹53.5 Cr, up 18% YoY from ₹45.5 Cr in Q1 FY25 (Page 7 & 6). Key concall takeaways from Chemcon Speciality Chemicals Ltd's Q1…

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Arthneeti Pro · Annual

Jubilant Ingrevia Ltd and 15K+ more earnings calls,
for less than your morning chai

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access

Frequently Asked Questions

What were Jubilant Ingrevia Ltd Q1 FY26 results?

Specialty Chemicals and Nutrition segments expected to sustain strong growth; these now contribute ~63% of revenue and 90% of EBITDA. Specialty and Nutrition segments contribute ~63% of revenue and ~90% of EBITDA, expected to sustain strong growth and margin expansion.

What is Jubilant Ingrevia Ltd share price analysis?

Jubilant Ingrevia Ltd currently shows a neutral. The stock trades at a P/E of 36.9 with a market cap of ₹11,738 Cr. Investors should review the full earnings analysis for detailed insights.

Is Jubilant Ingrevia Ltd planning capital expenditure?

Rs. 2000 crore invested recently, with 70% allocated to specialty chemicals, mainly for multipurpose and dedicated plants serving CDMO and Fine Chemicals businesses.

Keep Jubilant Ingrevia Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.